Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Novartis Files For Approval Of Rasilez; Speedel Partner

April 26, 2006

By Aaron Lorenzo

Novartis Files For Approval Of Rasilez; Speedel Partner

April 26, 2006

By Aaron Lorenzo

DOV Shares Crushed After Phase III Bicifadine Failure

April 26, 2006

By Aaron Lorenzo

Poor Phase III data nearly halved DOV Pharmaceutical Inc.'s stock value Tuesday after the findings were unveiled late Monday. (BioWorld Today)

Government Analysis Of SBIR Eligibility Questioned By Some

April 25, 2006

By Aaron Lorenzo

Government Analysis Of SBIR Eligibility Questioned By Some

April 25, 2006

By Aaron Lorenzo

Omrix Prices $34M IPO For Sealants, Immunotherapies

April 24, 2006

By Aaron Lorenzo

Omrix Prices $34M IPO For Sealants, Immunotherapies

April 24, 2006

By Aaron Lorenzo

Novartis Files For Approval Of Rasilez; Speedel Partner

April 21, 2006

By Aaron Lorenzo

MedImmune Strikes Deal With Elusys; Earnings Drop Shares

April 21, 2006

By Aaron Lorenzo

MedImmune Strikes Deal With Elusys; Earnings Drop Shares

April 21, 2006

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...